Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden

Summary

CAPTURE is a prospective, interventional, randomized, phase 2, double-blind, placebo-controlled study assessing the therapeutic add-on effect of the balanced THC/CBD extract (Cannabis extract Avextra 10/10 oral solution) on symptom burden in patients with advanced oncological disease receiving active treatment with WHO level II or III opioids and adjuvants therapies, compared to placebo, as measured by the Edmonton Symptom Assessment System Total Symptom Distress Score (ESAS-TSDS) at 8 weeks post randomization.

Timeline

Start

2026-04-01

Primary completion

2028-01-01

Completion

2028-12-31

Drugs

Indications